AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18436293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (extensively hydrolyzed formula)
Number of subjects: 119
Study 18436293 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 119
Study 18436293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 20348032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist led educational outreach (SOS)
Number of subjects: 4040
Study 20348032 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4040
Study 16273644 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (Sb) 0.5 g bid PO for 6 days
Number of subjects: 10
Study 16273644 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 10
Study 12018879 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 92
Study 12018879 — intervention group
Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 92
Study 10434909 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized ultrasonic technique
Number of subjects: 15
Study 10434909 — intervention group
Group type: COMPARATOR
Intervention: Normal non-weightbearing heel pad thickness measurement
Number of subjects: 15
Study 7913906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of 250 micrograms somatostatin
Number of subjects: 36
Study 7913906 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of somatostatin after bolus injection
Number of subjects: 36
Study 7913906 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 36
Study 3293417 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg twice daily)
Number of subjects: 0
Study 3293417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11759857 — intervention group
Group type: EXPERIMENTAL
Intervention: Envelope technique (E)
Number of subjects: 21
Study 11759857 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap combined with connective tissue graft (CP)
Number of subjects: 21
Study 30733182 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory community mobilisation (PLA)
Number of subjects: 11454
Study 30733182 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth mobile phone messaging
Number of subjects: 11454
Study 30733182 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 11454
Study 29555492 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular local anesthetic infiltration
Number of subjects: 99
Study 29555492 — intervention group
Group type: COMPARATOR
Intervention: Psoas compartment block (PCB)
Number of subjects: 99
Study 27541442 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders and free topical corticosteroid medication
Number of subjects: 209
Study 27541442 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up without reminders or free medication
Number of subjects: 209
Study 27541442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with suture removal instructions
Number of subjects: 209
Study 27541442 — intervention group
Group type: COMPARATOR
Intervention: Control group not told about suture removal
Number of subjects: 209
Study 24894197 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium administration
Number of subjects: 5001
Study 24894197 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E administration
Number of subjects: 5001
Study 24894197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5001
Study 22048460 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice daily for weeks 2-8)
Number of subjects: 120
Study 22048460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20369762 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP of 10 cmH2O during bypass
Number of subjects: 44
Study 20369762 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPAP during bypass)
Number of subjects: 44
Study 17368328 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative response to cold testing prior to RCT
Number of subjects: 83
Study 17368328 — intervention group
Group type: COMPARATOR
Intervention: Sham cold test after demonstrating soft tissue signs
Number of subjects: 83
Study 14751571 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 injection
Number of subjects: 81
Study 14751571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 11599686 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza vaccine (FLU-AD; n = 204)
Number of subjects: 308
Study 11599686 — intervention group
Group type: COMPARATOR
Intervention: Conventional subunit influenza vaccine (AGRIPPAL S1; n = 104)
Number of subjects: 308
Study 9844794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (mean final dose, 2.8 mg daily)
Number of subjects: 20
Study 9844794 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (mean final dose, 435 mg daily)
Number of subjects: 20
Study 7986226 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to histone (H2A-H2B)-DNA complexes in patients with scleroderma-related disorders
Number of subjects: 150
Study 7986226 — intervention group
Group type: COMPARATOR
Intervention: Antibodies to histone (H2A-H2B)-DNA complexes in patients with systemic lupus erythematosus (SLE)
Number of subjects: 150
Study 2929803 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap-opera style videotape intervention
Number of subjects: 0
Study 2929803 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupon redemption for free condoms
Number of subjects: 0
Study 2929803 — intervention group
Group type: COMPARATOR
Intervention: Control group (no videotape)
Number of subjects: 0
Study 31813108 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-Free and Casein-Free (GFCF) diet
Number of subjects: 37
Study 31813108 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (including gluten and casein)
Number of subjects: 37
Study 31813108 — intervention group
Group type: EXPERIMENTAL
Intervention: GFCF diet
Number of subjects: 37
Study 31813108 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 37
Study 29529627 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 80
Study 29529627 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 80
Study 29529627 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS
Number of subjects: 80
Study 29529627 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 28107765 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐spectrum colonoscopy (FSC)
Number of subjects: 220
Study 28107765 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy with right‐colon retroflexion (CC/R)
Number of subjects: 220
Study 25820017 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 168
Study 25820017 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (IFX)
Number of subjects: 168
Study 22786764 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (combined leucovorin, 5-fluoruracil, and oxaliplatin)
Number of subjects: 170
Study 22786764 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (combined capecitabine and oxaliplatin)
Number of subjects: 170
Study 22786764 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute OXLIPN symptoms
Number of subjects: 170
Study 20445570 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Angiotensin II receptor blocker
Number of subjects: 13542
Study 20445570 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Diuretics
Number of subjects: 13542
Study 18460481 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2 capsules of 1 gm per day)
Number of subjects: 86
Study 18460481 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (2 capsules of 1 gm per day)
Number of subjects: 86
Study 18460481 — intervention group
Group type: EXPERIMENTAL
Intervention: Hempseed oil (2 capsules of 1 gm per day)
Number of subjects: 86
Study 18460481 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules of 1 gm per day)
Number of subjects: 86
Study 18460481 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (Fish oil, Flaxseed oil, Hempseed oil, Placebo)
Number of subjects: 86
Study 16539558 — intervention group
Group type: EXPERIMENTAL
Intervention: Kurasper F adhesive resin
Number of subjects: 0
Study 16539558 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Bond adhesive resin
Number of subjects: 0
Study 16539558 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Bond C&B adhesive resin
Number of subjects: 0
Study 16539558 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond XT adhesive resin
Number of subjects: 0
Study 16539558 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain Liner M
Number of subjects: 0
Study 16539558 — intervention group
Group type: COMPARATOR
Intervention: All adhesive resins
Number of subjects: 0
Study 14674902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin 100 mg twice a day
Number of subjects: 57
Study 14674902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 200 mg day‐1
Number of subjects: 57
Study 14674902 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 200 mg three times a day
Number of subjects: 57
Study 14674902 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 100 mg three times a day
Number of subjects: 57
Study 14674902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 14674902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin 50 mg twice a day
Number of subjects: 57
Study 10553854 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: sevoflurane anesthesia via an airway endoscopy mask
Number of subjects: 100
Study 10553854 — intervention group
Group type: COMPARATOR
Intervention: Group B: total IV anesthesia with propofol, fentanyl, atracurium
Number of subjects: 100
Study 9118417 — intervention group
Group type: EXPERIMENTAL
Intervention: Perivesical fat closure
Number of subjects: 89
Study 9118417 — intervention group
Group type: COMPARATOR
Intervention: No fat closure
Number of subjects: 89
Study 1864532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at night
Number of subjects: 200
Study 1864532 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg at night
Number of subjects: 200
Study 6309436 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (10-40 mg/day)
Number of subjects: 15
Study 6309436 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg/day)
Number of subjects: 15
Study 6309436 — intervention group
Group type: COMPARATOR
Intervention: MK-421 (10 mg/day)
Number of subjects: 15
Study 6309436 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg/day) plus MK-421 (10 mg/day)
Number of subjects: 15
Study 30630455 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress indicators
Number of subjects: 1191
Study 30630455 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal ideation
Number of subjects: 1191
Study 30630455 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling down, depressed or hopeless
Number of subjects: 1191
Study 30630455 — intervention group
Group type: EXPERIMENTAL
Intervention: Having no hope for the future
Number of subjects: 1191
Study 28421646 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week intervention programme targeting 10 cross-curriculum words
Number of subjects: 35
Study 27052071 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-axis ultrasound-guided cannulation
Number of subjects: 0
Study 27052071 — intervention group
Group type: COMPARATOR
Intervention: Short-axis ultrasound-guided cannulation
Number of subjects: 0
Study 27052071 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameter of IJ vein
Number of subjects: 0
Study 27052071 — intervention group
Group type: EXPERIMENTAL
Intervention: Margin of safety
Number of subjects: 0
Study 23792711 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month group intervention
Number of subjects: 80
Study 23792711 — intervention group
Group type: COMPARATOR
Intervention: individual-enhanced standard-of-care condition
Number of subjects: 80
Study 27933598 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP mouthwash (0.103% DHEP in aqueous solution)
Number of subjects: 80
Study 27933598 — intervention group
Group type: COMPARATOR
Intervention: diclofenac mouthwash (0.074% free diclofenac in aqueous solution)
Number of subjects: 80
Study 19258147 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Active Motion Protocol (IAMP)
Number of subjects: 50
Study 19258147 — intervention group
Group type: COMPARATOR
Intervention: Conventional Immobilization
Number of subjects: 50
Study 17332211 — intervention group
Group type: EXPERIMENTAL
Intervention: Children < 2 years of age with bilateral acute otitis media
Number of subjects: 824
Study 17332211 — intervention group
Group type: EXPERIMENTAL
Intervention: Children >= 2 years of age with unilateral acute otitis media
Number of subjects: 824
Study 15710792 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 57
Study 15710792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 57
Study 15710792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 12136454 — intervention group
Group type: EXPERIMENTAL
Intervention: High tourniquet pressure (400 mmHg)
Number of subjects: 86
Study 12136454 — intervention group
Group type: COMPARATOR
Intervention: Low tourniquet pressure (100 mmHg above systolic pressure)
Number of subjects: 86
Study 10072097 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength test (two sets of 12 repetitions at 12-repetition maximum and four sets of 5 repetitions at 5-repetition maximum)
Number of subjects: 32
Study 10072097 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training program (8 weeks)
Number of subjects: 32
Study 10072097 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group (control)
Number of subjects: 32
Study 10072097 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group
Number of subjects: 32
Study 7674236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap (120 mg/day)
Number of subjects: 32
Study 7674236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7674236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap
Number of subjects: 32
Study 2402930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 137
Study 2402930 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 137
Study 7016643 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (3 mg/3 min and 0.8 mg/min)
Number of subjects: 7
Study 7016643 — intervention group
Group type: COMPARATOR
Intervention: Control (no adrenergic blockade)
Number of subjects: 7
Study 7016643 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (5 mg stat and 0.5 mg/min)
Number of subjects: 7
Study 31434140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 0
Study 31434140 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated administration of ketamine
Number of subjects: 0
Study 31434140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (various applications: intravenous, subcutaneous, intramuscular, intranasal)
Number of subjects: 0
Study 31434140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 29125216 — intervention group
Group type: EXPERIMENTAL
Intervention: Pēpi‐Pod sleep space programme
Number of subjects: 240
Study 29125216 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 240
Study 27098290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g·kg‐1BM of NaHCO3
Number of subjects: 16
Study 27098290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g·kg‐1BM of NaHCO3
Number of subjects: 16
Study 27098290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g·kg‐1BM of NaHCO3
Number of subjects: 16
Study 23998788 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal vitamin K1 administration (Group A)
Number of subjects: 90
Study 23998788 — intervention group
Group type: COMPARATOR
Intervention: No antenatal vitamin K1 administration (Group B)
Number of subjects: 90
Study 23998788 — intervention group
Group type: COMPARATOR
Intervention: Healthy full term newborns (Group C)
Number of subjects: 90
Study 23089675 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief group alcohol intervention (two 45-min sessions based on motivational interviewing techniques)
Number of subjects: 668
Study 23089675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 668
Study 21095491 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (recombinant human erythropoietin 4000 IU SC)
Number of subjects: 20
Study 21095491 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (recombinant human erythropoietin 4000 IU SC)
Number of subjects: 20
Study 18297183 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (six hour intervention delivered in two sessions on two consecutive Saturdays)
Number of subjects: 832
Study 18297183 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 832
Study 15705086 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (antimuscarinic drug)
Number of subjects: 0
Study 12939945 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberine and citotoflavine (metabolic antihypoxants)
Number of subjects: 44
Study 12939945 — intervention group
Group type: EXPERIMENTAL
Intervention: Perftoran and cytoflavin (added to therapy scheme)
Number of subjects: 44
Study 12939945 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (intensive therapy without metabolic antihypoxants)
Number of subjects: 44
Study 11004048 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-gauge Atraucan needle
Number of subjects: 1002
Study 11004048 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke needle
Number of subjects: 1002
Study 11004048 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-gauge Gertie Marx (GM) needle
Number of subjects: 1002
Study 11004048 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-gauge Sprotte needle
Number of subjects: 1002
Study 11004048 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Whitacre needle
Number of subjects: 1002
Study 8837981 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 0
Study 8837981 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 1421975 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhizae (SM) plus vitamin C, ATP, CoA (n = 30)
Number of subjects: 60
Study 1421975 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C, ATP, CoA (n = 30)
Number of subjects: 60
Study 6536840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of potassium chloride
Number of subjects: 8
Study 6536840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of potassium/magnesium chloride
Number of subjects: 8
Study 6536840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of potassium-(D,L)-aspartate
Number of subjects: 8
Study 6536840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of potassium/magnesium-(D,L)-aspartate
Number of subjects: 8
Study 6536840 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 8
Study 3539027 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal or banked breast milk
Number of subjects: 186
Study 3539027 — intervention group
Group type: COMPARATOR
Intervention: Artificial preterm formula
Number of subjects: 186
Study 31374218 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (10 mg week 1, 20 mg week 2)
Number of subjects: 20
Study 31374218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29916560 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure medications (specific drugs not mentioned)
Number of subjects: 0
Study 29916560 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment methods for randomized clinical trials
Number of subjects: 0
Study 29916560 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing medications thoroughly in both sexes
Number of subjects: 0
Study 27343887 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training
Number of subjects: 180
Study 27343887 — intervention group
Group type: COMPARATOR
Intervention: Parent Education
Number of subjects: 180
Study 24355874 — intervention group
Group type: EXPERIMENTAL
Intervention: Early plasma Angiopoietin‐2 (Ang‐2) levels
Number of subjects: 115
Study 22863644 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconnective Healers
Number of subjects: 81
Study 22863644 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki Masters
Number of subjects: 81
Study 22863644 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 81
Study 20398558 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP technique
Number of subjects: 127
Study 20398558 — intervention group
Group type: COMPARATOR
Intervention: Simple stenting
Number of subjects: 127
Study 18713912 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine‐clonidine 150 microg (BC group)
Number of subjects: 96
Study 18713912 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine‐sufentanil (BS group)
Number of subjects: 96
Study 18713912 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine‐sufentanil‐clonidine 75 microg (BSC group)
Number of subjects: 96
Study 15673383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation guided by pace mapping of Koch's triangle (Group 2)
Number of subjects: 909
Study 15673383 — intervention group
Group type: COMPARATOR
Intervention: Conventional slow pathway ablation (Group 1)
Number of subjects: 909
Study 12950571 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond-coated ultrasonic retrotips (DC)
Number of subjects: 85
Study 12950571 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium nitride-coated retrotips (KiS)
Number of subjects: 85